stoxline Quote Chart Rank Option Currency Glossary
  
Biogen Inc. (BIIB)
223.32  0.84 (0.38%)    02-23 16:00
Open: 223.43
High: 225.8
Volume: 900,915
  
Pre. Close: 222.48
Low: 221.5
Market Cap: 32,462(M)
Technical analysis
2024-02-23 4:35:18 PM
Short term     
Mid term     
Targets 6-month :  278.25 1-year :  294.53
Resists First :  238.23 Second :  252.16
Pivot price 231.57
Supports First :  215.68 Second :  179.44
MAs MA(5) :  221.04 MA(20) :  235.37
MA(100) :  244.75 MA(250) :  265.86
MACD MACD :  -7.4 Signal :  -6
%K %D K(14,3) :  19.9 D(3) :  14.8
RSI RSI(14): 34.5
52-week High :  319.76 Low :  215.68
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BIIB ] has closed above bottom band by 30.3%. Bollinger Bands are 69% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 225.82 - 226.61 226.61 - 227.33
Low: 219.22 - 220.24 220.24 - 221.17
Close: 221.71 - 223.13 223.13 - 224.42
Company Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 24 Feb 2024
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and ... - GlobeNewswire

Fri, 23 Feb 2024
Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Fri, 23 Feb 2024
Biogen granted EU backing for ALS therapy (NASDAQ:BIIB) - Seeking Alpha

Wed, 21 Feb 2024
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings - Simply Wall St

Tue, 20 Feb 2024
Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Wed, 14 Feb 2024
Biogen Inc. (NASDAQ:BIIB) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers—General
Shares Out 145 (M)
Shares Float 145 (M)
Held by Insiders 0.6 (%)
Held by Institutions 93 (%)
Shares Short 3,060 (K)
Shares Short P.Month 3,910 (K)
Stock Financials
EPS 7.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 102.13
Profit Margin 11.8 %
Operating Margin 19.3 %
Return on Assets (ttm) 4.5 %
Return on Equity (ttm) 8.2 %
Qtrly Rev. Growth -6.2 %
Gross Profit (p.s.) 0
Sales Per Share 67.69
EBITDA (p.s.) 16.37
Qtrly Earnings Growth -55 %
Operating Cash Flow 1,550 (M)
Levered Free Cash Flow 971 (M)
Stock Valuations
PE Ratio 28.02
PEG Ratio 5
Price to Book value 2.18
Price to Sales 3.29
Price to Cash Flow 20.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android